返回
CNS Pharmaceuticals Inc（CNSP）價格
CNSP 股價走勢圖
CNSP 收益
CNS Pharmaceuticals Inc
$7.04
-4.47%
$-0.33
收盤價：Jan 16, 16:00:00 GMT-5
$6.77
-3.83%
$-0.27
盤前：Jan 20, 08:22:58 GMT-5
關鍵數據
前收市價
$7.37
開盤價
$6.91
當日範圍
$6.77 - $7.39
52週區間
$4.93 - $114
交易量
67.5K
平均成交量
37.3K
每股盈餘 (TTM)
-130.84
股息收益率
--
市值
$4.1M
什麼是 CNSP？
CNS Pharmaceuticals, Inc. is a preclinical stage pharmaceutical company, which engages in the development of anticancer drug candidates for the treatment of primary and metastatic brain and central nervous system tumors. The company is headquartered in Houston, Texas and currently employs 4 full-time employees. The company went IPO on 2019-11-08. The firm's drug candidate, Berubicin, is the first anthracycline to appear to cross the blood-brain barrier. Berubicin is the subject of the Company's late-stage, fully-enrolled, global clinical trial for the treatment of glioblastoma multiforme (GBM), an aggressive and incurable form of brain cancer. The firm's drug candidate, TPI 287, is an abeotaxane which stabilizes microtubules and inhibits cell division, causing apoptosis and cell death. TPI 287 has shown the potential to cross the blood-brain barrier and treat central nervous system (CNS) tumors.